Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. In addition to genetic changes, gene hypermethylation is an alternative mechanism of tumor suppressor gene inactivation in MM. The cyclin-dependent kinase inhibitor 1 (CDKN2B or p15
Introduction
In tumor cells, the pattern of methylation is changed. There is a growing list of tumor suppressor genes (TSGs) with increased methylation frequency at promoter region 1 with detectable gene-body DNA hypomethylation. 2 Since aberrant hypermethylation of CpG dinucleotides in the promoter of TSG is a commonly observed epigenetic modification in human tumors, [3] [4] [5] analysis of specific gene promoter methylation as a tool for diagnosis and prognosis of tumors has been widely applied in many different tumors, including multiple myeloma (MM). 6, 7 MM is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. 8 In the US, MM accounts for ~1% of all malignant diseases or ~15% of all hematological malignancies and is the second most common form of hematological malignancies. 9 Clinically, MM starts with immortalization of a postgerminal center B-cell and presents as asymptomatic monoclonal gammopathy of undetermined significance (MGUS).
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li et al MGUS is considered as the precursor of MM, since it is able to progress to symptomatic MM at a rate of 1% per year. 10 MGUS plasma cells share many abnormal characteristics with MM plasma cells. Cytogenetic abnormalities, such as 14q32 translocations, deletions of 13q, and numeric gains of multiple chromosomes, have been discovered at the level of MGUS, indicating early onset of karyotypic instability in monoclonal gammopathies. 11 Genetically, MM develops and progresses due to the accumulation of multiple defined pathological genetic events. By genome-wide methylation microarrays or gene-specific hypermethylation analysis, aberrant DNA methylation in MM has been found to inactivate a number of protein-coding TSGs in the process of regulating cell cycle progression, cell growth, or apoptosis, which include cyclin-dependent kinase inhibitor 2A (p16 CDKN2A ), cyclin-dependent kinase inhibitor 2B (p15
CDKN2B
or p15
INK4B
), death-associated protein kinase (DAP), secreted frizzled-related protein 2, suppressor of cytokine signaling 1 (SOCS1), 12, 13 and microribonucleic acid. 14 However, there is a lack of a thorough summary of different studies on p15
epigenetic methylation in MM that can provide the reader with extensive information on whether an effect exists and what size the effect is. In the present study, we will carry out a meta-analysis of p15 INK4B methylation status in MM and in its precursor MGUS.
Methods
search strategy
Medline, PubMed, Web of Science, Scopus, and Embase were searched in April 2014 using the search terms "p15", "p15
INK4B
", "cyclin-dependent kinase inhibitor 2B", "methylation", "multiple myeloma", and "clinical studies". Investigations identified through the search approach as described were screened by titles first, then by abstracts of the publications. After exclusion of nonrelevant publications and identification of duplicates from the different databases, the remaining papers were evaluated in the full-text version for inclusion and exclusion criteria and for relevant articles in the reference lists. All clinical studies except case reports were chosen: eg, randomized controlled trials, cohort studies, case control studies, and case series. The language of publication was restricted to English and Chinese. All searched data were retrieved. Authors' bibliographies and references of selected studies were also searched for other relevant studies. The most complete study was chosen to avoid duplication if the same patient populations were reported in several publications.
selection criteria
We collected all eligible articles about the relationship between p15 INK4B methylation and/or expression and clinicopathological features and clinical outcomes in MM patients in this meta-analysis. Diagnosis and staging classification of MM must follow the standard criteria as described previously. 15, 16 In detail, MM requires evidence of bone marrow plasmacytosis, M-protein in serum or urine, and osteolytic bone lesions and the presence of myeloma-related organ or tissue impairment. MGUS is characterized 15, 16 by monoclonal protein 30 g/L and bone marrow clonal cells 10% with no evidence of MM, other B-cell proliferative disorders, or amyloidosis. Normal controls are referred to as the normal peripheral blood samples or bone marrow aspirates obtained from the healthy donors. Studies meeting the following inclusion criteria were included: 1) p15
INK4B
methylation and/or expression evaluated in the circulation and/or bone marrow, 2) research that revealed the relationship between p15 INK4B methylation and/or expression and MM clinicopathological parameters and prognosis, 3) p15
methylation and/or expression examined by methylationspecific polymerase chain reaction (MSP) or Southern blot, 4) articles that were published as full papers in English or Chinese, and 5) articles that provided sufficient information to estimate hazard ratio (HR) about overall survival (OS) and 95% confidence interval (CI) and probabilities for progression-free survival (PFS) where applicable. The exclusion criteria included the following: 1) letters, reviews, case reports, conference abstracts, editorials, expert opinion, and non-English language papers; 2) articles with no information on OS or those that could not calculate the HR about OS from the given information; and 3) all publications regarding in vitro/ex vivo studies, cell lines, and human xenografts.
Data extraction
Two investigators independently extracted data from eligible studies. Disagreements were resolved by discussion and consensus. Two investigators reviewed all of the articles that fit inclusion and exclusion criteria. The following information was recorded for each study: the first author name, year of publication, sample source, number of cases, clinicopathological parameters, stage, p15 INK4B methylation and/or expression, and patient survival. Data for study characteristics and clinical response were summarized and turned into table format. Heterogeneity of investigation was evaluated to determine whether the data of the various studies could be analyzed in a meta-analysis. The database search generated 25 articles from Medline, PubMed, the Web of Science, Scopus, and Embase. After initial screening of all titles, abstracts, and eligibility, 12 full-text studies were retracted for more detailed assessment. The search of the article references did not produce additional publications. Eventually, 12 publications met the inclusion criteria for qualitative study and for metaanalysis. The article search and study selection are depicted in Figure 1 .
Results
Identification of relevant studies
Twenty-five publications were identified by the search method as described. Thirteen of those were excluded due to laboratory studies, nonoriginal articles (review), or studies irrelevant to the current analysis. Eventually, there were 12 studies included in the final meta-analysis (Figure 1 ). 17 
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sensitivity analyses and publication bias
A sensitivity analysis in which one study was removed at a time was conducted to assess the result stability. The pooled ORs were not significantly changed, indicating the stability of our analyses. The funnel plots were largely symmetric ( Figure 5 ), suggesting there were no publication biases in the meta-analysis of p15 INK4B methylation/expression and clinicopathological features.
Discussion
MM is an incurable B-cell tumor. Pathogenesis involves upregulation of D-type cyclins, activation of oncogenes, and inactivation of TSGs. 12 A better understanding of inactivation of TSGs by gene hypermethylation in MM pathogenesis will lead to more rational combinations of drugs targeting true epigenetic changes and cytotoxic actions. Since gene hypermethylation is a common mechanism of TSG inactivation, various approaches have been used to elucidate the role of gene hypermethylation in MM, including a candidate gene approach, microarray approach for genes upregulated by hypomethylating agents, and a cancer pathway approach, which enables a comprehensive picture of the involvement of multiple TSGs in MM. 12 The main TSGs inactivated by hypermethylation in MM are as follows: 1) the INK4 and CIP/ KIP families of cyclin-dependent kinase inhibitors, CDKN2B (p16
INK4A
) and CDKN2A (p15 The present study focused on the involvement of epigenetic changes of p15 INK4B in MM pathogenesis and prognosis. CD138 is a plasma biomarker. Several included studies in this meta-analysis sorted CD138 + plasma cells 22, 23 for MSP analysis, while others used unsorted mononuclear cells. 26 By reviewing various studies on methylation examination in B-cell malignancies for different TSGs such as p16 INKAB and p15
INK4B
, we found that the reported methylation frequencies of these tested genes were comparable in both types of studies. 22, [29] [30] [31] [32] [33] [34] Therefore, we concluded that CD138 + cells sorting is not mandatory for methylation evaluation by MSP technique. In other words, sorting CD138 + or not does not affect the included data analysis.
Epigenetic changes contribute to tumorigenesis and affect initial steps in malignant transformation by altering genome stability and regulating gene expression. 35 Analysis of the methylome of CD138 + cells by ligation-mediated polymerase chain reaction assay from different stages of myelomagenesis demonstrated qualitative epigenetic differences between premalignant and malignant stages. 35 Plasma cells from MGUS, a premalignant and early stage of myeloma, were characterized by striking widespread hypo methylation, while gene-specific hypermethylation was found to occur in the advanced stages of myeloma. Furthermore, aberrant demethylation in MGUS occurred primarily in CpG islands, whereas differentially methylated loci in cases of myeloma occurred predominantly outside of CpG islands and affected distinct sets of gene pathways. 35 These results indicate widespread stage-specific epigenetic changes during myelomagenesis and that early demethylation can be a potential contributor to genome instability seen in myeloma. 35 In our included studies, there was a significant difference in hypermethylation status of p15 INK4B genes at promoter region between patients with MGUS and MM, which reflects the stage-specific epigenetic changes during myelomagenesis. However, all the studies fail to give information about the methylation situation outside promoter region.
Methylation patterns may be useful as prognostic indicators in MM. Despite possible variations between methods utilized, heterogeneity of patients, and other unknown 22 By univariate analysis, hypermethylation of DAPK (P0.001) and RARβ (P=0.01) genes was also identified as an adverse prognostic factor. Median OS of MM patients with hypermethylation in DAPK (4 months) and RARβ (34 months) was significantly lower than in those without hypermethylation.
